ArticleMaterials today. Bio2025
Multi-responsive nanocomposite hydrogel for synergistic photothermal-chemotherapy to prevent postoperative recurrence and metastasis of uveal melanoma.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postoperative recurrence and metastasis remain major challenges in improving the prognosis of uveal melanoma (UM). Herein, we developed a chitosan-based injectable multi-responsive nanocomposite hydrogel (CPT NPs gel) for localized and synergistic photothermal-chemotherapy following tumor resection. This hydrogel co-encapsulates pH/GSH-responsive camptothecin-loaded nanoparticles (CPT NPs) and polydopamine, forming a porous, self-healing network that persists in vivo for over 28 days. Upon near-infrared (NIR) irradiation, the hydrogel rapidly elevates the local temperature to approximately 60 °C within 40 s, enabling efficient ablation of residual tumor tissue at the surgical site. Concurrently, CPT NPs are sustainably released from the hydrogel and enter systemic circulation, where they undergo charge reversal upon encountering the mildly acidic microenvironment of metastatic lesions to enhance cellular uptake and subsequently disassemble in response to intracellular GSH, thereby eliminating disseminated UM cells. In a partially resected MuM-2B tumor-bearing mouse model, CPT NPs gel combined with NIR irradiation completely abrogated local tumor recurrence and significantly reduced pulmonary metastasis, limiting metastatic infiltration to less than 1 % without observable systemic toxicity. Overall, this study presents a promising multifunctional therapeutic platform for the synergistic prevention of UM recurrence and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.